<DOC>
	<DOCNO>NCT02630264</DOCNO>
	<brief_summary>Recombinant human endostatin adenovirus injection novel anti-tumor gene therapy drug . E10A contain recombinant human endostatin gene second-generation recombinant adenovirus vector . After transfection tumor cell . E10A express human endostatin , inhibit vascular endothelial cell proliferation tumor angiogenesis , block tumor blood supply , thereby specifically inhibit tumor growth induce apoposis tumor cell . Both pre-clinical animal model demonstrate anti-tumor activity E10A . The safety efficacy E10A treat head neck cancer also demonstrate Phase I Phase II study .</brief_summary>
	<brief_title>E10A Treatment Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>Phase II Clinical Study From March 2008 December 2010 Safety efficacy intratumoral injection E10A cisplatin paclitaxel evaluate multicenter , open-label , randomized clinical study patient advance head neck squamous cell carcinoma . 136 eligible patient recruit randomly assign . Patients locally advance metastatic head neck squamous cell carcinoma nasopharyngeal carcinoma suitable operation radiotherapy randomly assign receive E10A plus chemotherapy every 21 maximum six cycle receive chemotherapy . The primary end point objective response rate ( RR ) , define proportion patient complete response ( CR ) partial response ( PR ) target tumor lesion . The secondary end point objective disease control rate ( DCR , stable disease ( SD ) + PR + CR target tumor lesion ) , overall RR , overall DCR , OS , progression-free survival ( PFS ) . The administration E10A benefit subgroups patient . In HNSCC patient , objective RR 36.5 % ( 15/41 ) E10A administration , exhibit trend exceed rate 20.0 % ( 7/35 ) control group ( P = 0.090 ; OR : 0.43 ) , whereas objective RR 44.4 % ( 12/27 ) versus 40.6 % ( 13/32 ) NPC patient ( P = 0.487 ; OR : 0.86 ) . Patients previously receive chemotherapy E10A group 44.8 % ( 12/29 ) objective RR , whereas patient control group 22.6 % objective RR ( 7/31 ; P = 0.06 , OR : 0.36 ) . In contrast , patient without previous chemotherapy similar RR group ( 34.3 versus 39.4 % ; P = 0.426 , OR : 1.25 ) . The difference Kaplan-Meier estimate PFS favor chemotherapy plus E10A , result 3.43-month improvement . With median follow-up 10.47 month , median PFS 3.60 month ( interquartile range : 2.60-7.63 ) control group 7.03 month ( interquartile range : 3.27-13.73 ) E10A group . As The median PFS 3.60 month ( interquartile range : 2.60-7.63 ) control group 7.03months ( interquartile range : 3.27-13.73 ) E10A group . The OS E10A group relatively prolong different subgroup compare control ( e.g. , 13.37 month versus 9.67 month HNSCC patient , 13.03 month versus 10.50 month receive prior treatment ; Figure 1 ) , result translate significantly superior survival .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1 . Patients older 18 year histologically cytologically prove locoregionally advanced metastatic HNSCC ( exclude NPC ) suitable operation radiotherapy 2 . A life expectancy≧12 week . 3 . Patients require least one measurable ( image photograph comply RECIST ) lesion large diameter ≧2 cm suitable intratumoral injection E10A , 4 . Not received chemotherapy , radiotherapy , biotherapy within 4 week . 5 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 02 . 6 . Adequate bone marrow , renal , liver function . 1 . Known allergy study drug . 2 . The presence important blood vessels/nerves ulceration target lesion suitable injection . 3 . Tumor relapse within 6 month paclitaxel chemotherapy . 4 . Severe coagulation disorder bleed tendency . 5 . Severe uncontrolled medical condition . 6 . Recent history myocardial infarction acute infection , pregnancy lactation , symptomatic brain metastasis 7 . A history corticosteroid immunosuppressive use within four week study entry 8 . Received chemotherapy radiotherapy within four week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>clinical trial</keyword>
	<keyword>Recombinant Human Endostatin Adenovirus</keyword>
	<keyword>randomize</keyword>
</DOC>